title: Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
abstract: Since RGD fiber-mutant adenovirus vector (AdRGD), which contains an alphav-integrin tropism, is highly efficient in gene transduction to melanoma, the AdRGD-mediated herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) system is an attractive approach for melanoma treatment. However, the intratumoral injection of AdRGD causes limited transgene expression in healthy normal tissue, due to unwanted vector spread. Herein, we describe our attempt to overcome this limitation related to the safety of HSVtk/GCV treatment by using AdRGD carrying either melanoma-specific tyrosinase (Tyr) promoter or tumor-specific telomerase reverse transcriptase (TERT) promoter instead of universal cytomegalovirus promoter. Our in vitro study revealed that Tyr promoter-regulated AdRGD exhibited high transgene expression specificity for melanoma cells, and that TERT promoter-regulated AdRGD could induce efficient gene expression in tumor cells, but was relatively quiescent in normal cells. Anti-B16BL6 melanoma effects in mice injected intratumorally with AdRGD-Tyr/HSVtk or AdRGD-TERT/HSVtk, after which GCV was injected intraperitoneally for 10 days, were comparable to those in mice injected with AdRGD-CMV/HSVtk at 10 times less vector dosage. On the other hand, AdRGD-Tyr/HSVtk and AdRGD-TERT/HSVtk did not induce severe adverse effects even when they were intravenously injected into mice at 10(9) plaque-forming units (PFU), whereas mice injected with AdRGD-CMV/HSVtk at 10(8) PFU exhibited body weight reduction and serum level increase of biochemical enzymes for hepatotoxicity. These results indicate that AdRGD combined with transcriptional regulation using Tyr or TERT promoter is a potentially useful and safe vector system for suicide gene therapy for melanoma.
authors.affiliation: Research Institute for Microbial Diseases, Osaka University, Japan. okada@mb.kyoto-phu.ac.jp
authors.forename: Yuka
authors.initials: Y
authors.lastname: Okada
authors.forename: Naoki
authors.initials: N
authors.lastname: Okada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Mizuguchi
authors.forename: Takao
authors.initials: T
authors.lastname: Hayakawa
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Tadanori
authors.initials: T
authors.lastname: Mayumi
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001835:Body Weight; D004268:DNA-Binding Proteins; D018014:Gene Transfer Techniques; D041722:Genes, Transgenic, Suicide / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D015552:Injections, Intralesional; D008546:Melanoma, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D014442:Monophenol Monooxygenase / Q000235:genetics; D009842:Oligopeptides / Q000737:chemistry / Q000235:genetics*; D011401:Promoter Regions, Genetic; D018139:Simplexvirus / Q000201:enzymology; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy; D019098:Telomerase / Q000235:genetics; D013937:Thymidine Kinase / Q000235:genetics*; D014161:Transduction, Genetic; D019076:Transgenes / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid; D014442:Monophenol Monooxygenase; D013937:Thymidine Kinase; C509186:TERT protein, human; D019098:Telomerase; C509187:Tert protein, mouse